CT-2A Orthotopic Mouse Model Service for Brain Cancer

The CT-2A orthotopic mouse model for brain cancer stands as one of the most translationally relevant syngeneic platforms for studying malignant glioma progression within a fully immunocompetent host. Alfa Cytology offers a comprehensive preclinical service encompassing stereotactic intracranial implantation, serial tumor monitoring, and integrated endpoint analysis, enabling you to evaluate therapeutic candidates against high-grade glioma in a physiologically authentic neuro-oncology setting.

Overview of CT-2A Orthotopic Mouse Model for Brain Cancer

The CT-2A orthotopic brain tumor model is generated by stereotactic injection of murine CT-2A astrocytoma cells into the caudate-putamen of syngeneic C57BL/6J mice, faithfully recapitulating the anatomic origin, infiltrative growth pattern, and hostile tumor microenvironment characteristic of human high-grade glioma. Originally established in 1992 by Seyfried and colleagues from a 20-methylcholanthrene-induced malignant astrocytoma, the CT-2A line exhibits hallmark glioblastoma features including high mitotic index, marked nuclear polymorphism, pseudopalisading necrosis, hemorrhage, and exuberant microvascular proliferation. Because this model is propagated in immunocompetent animals, it preserves endogenous immune surveillance mechanisms, allowing investigators to interrogate tumor-immune interactions, evaluate immunotherapeutic modalities, and assess agents that modulate the glioma stem cell niche—dimensions that remain inaccessible in immunodeficient xenograft systems.

Fig 1. A comparative diagram of the immune characteristics of four syngeneic GBM models (human model vs. mouse model: GL261/CT-2A/SB28/SMA-560). (Letchuman, Vijay, et al., 2022)

Unlike subcutaneous or flank implants, the intracranial CT-2A model maintains the blood-brain barrier, peritumoral edema dynamics, and hypoxic gradients that profoundly influence drug delivery and therapeutic resistance in clinical glioblastoma. The infiltrative nature of CT-2A tumors—characterized by satellite lesions extending into adjacent parenchyma and distant brain regions—mirrors the diffuse invasion pattern that frustrates surgical resection in patients. Furthermore, CT-2A cells readily form neurospheres under serum-free conditions, enriching for a glioma stem cell population that drives heightened proliferative and invasive capacities, thereby extending the model's utility to studies focused on tumor-initiating cells and recurrence mechanisms in an immunocompetent context.

Cell Line Information: CT-2A

The CT-2A cell line is a murine malignant astrocytoma line originally derived from a tumor induced by intracerebral implantation of the polycyclic aromatic hydrocarbon carcinogen 20-methylcholanthrene in a C57BL/6J mouse. The tumor was maintained through serial intracranial transplants prior to establishment as an adherent cell line, and it has since become a cornerstone model for preclinical neuro-oncology research. Below is a detailed summary of the key characteristics of the CT-2A cell line:

Our Services

Alfa Cytology specializes in the construction, validation, and longitudinal characterization of the CT-2A orthotopic brain tumor model, delivering a robust preclinical platform tailored to your glioma research objectives. From precision stereotactic surgery and perioperative neurologic monitoring to standardized histopathological and molecular endpoint analysis, our team ensures reproducible, high-quality data that advance your discovery pipeline from target engagement through lead optimization.

Workflow of CT-2A Orthotopic Mouse Model Construction

Construction of the CT-2A orthotopic brain tumor model relies on stereotactic intracranial injection to achieve precise anatomical targeting within the murine caudate-putamen, ensuring consistent tumor engraftment while minimizing surgical morbidity. The protocol integrates neurosurgical precision, standardized perioperative care, and rigorous endpoint analysis to yield a reproducible preclinical glioma platform. The essential steps are detailed below:

1. Preoperative Preparation and Anesthesia: Adult C57BL/6J mice (8–12 weeks old, female or male) are acclimatized for at least one week prior to surgery. On the day of procedure, mice are anesthetized with isoflurane (3–4% induction, 1.5–2% maintenance in medical oxygen) or an intraperitoneal cocktail of ketamine (90–100 mg/kg) and xylazine (10 mg/kg). The scalp is shaved and sterilized with alternating povidone-iodine and 70% ethanol scrubs. A heating pad maintains body temperature throughout the procedure.
2. Stereotactic Cranial Exposure and Burr Hole Creation: A midline scalp incision is made to expose the cranium, and bregma is identified as the primary stereotactic reference point. A dental drill is used to create a burr hole at the following coordinates relative to bregma: 0.5 mm anterior, 2.0–2.5 mm lateral to the right of the midline. The dura mater is gently perforated with a fine needle to facilitate smooth needle insertion without deflection.
3. Intracranial Cell Inoculation: CT-2A cells are harvested during logarithmic growth phase, washed in sterile PBS, and resuspended at a concentration of 1×10⁵ to 1×10⁶ cells per 5 µL in serum-free DMEM/F-12 or PBS. A 26-gauge Hamilton syringe mounted on a stereotactic frame is lowered through the burr hole to a depth of 2.5–3.0 mm below the dura mater (corresponding to the caudate-putamen). The cell suspension is infused slowly over 3–5 minutes to prevent backflow and reflux, followed by a 2-minute dwell period before gradual needle withdrawal.
4. Wound Closure and Postoperative Recovery: The burr hole is sealed with bone wax or a biocompatible adhesive, and the scalp incision is closed with surgical sutures or tissue adhesive. Mice are transferred to a heated recovery chamber and monitored until fully ambulatory. Postoperative analgesia (buprenorphine 0.05–0.1 mg/kg) is administered according to IACUC-approved protocols. Body weight and neurologic symptoms are scored at least three times per week using a standardized grading system (Grade 0: no symptoms; Grade 1: mild hemiparesis; Grade 2: moderate hemiparesis with unstable gait; Grade 3: hunched posture with severe hemiparesis or circling; Grade 4: moribund).
5. Longitudinal Tumor Monitoring and Imaging: Tumor growth is monitored through a combination of behavioral scoring, body weight tracking, and optional small-animal magnetic resonance imaging (MRI) or bioluminescence imaging (BLI) if luciferase-expressing CT-2A variants are employed. MRI sequences (T1-weighted with contrast, T2-weighted) enable noninvasive visualization of tumor volume, peritumoral edema, and necrotic regions at defined intervals. For neurosphere-derived CT-2A models, more frequent monitoring may be warranted due to accelerated growth kinetics.
6. Therapeutic Intervention and Response Assessment: Upon confirmation of established tumors (typically 7–14 days post-implantation), mice are randomized into treatment and control cohorts. Therapeutic agents may be delivered systemically (intraperitoneal, intravenous, oral gavage) or locally (intratumoral, convection-enhanced delivery). Response is evaluated through serial imaging, body weight trends, neurologic symptom scores, and overall survival curves. Optional pharmacokinetic sampling via tail-vein blood draws supports mechanism-of-action studies.
7. Endpoint Analysis and Histopathological Validation: At study termination—defined by ethical endpoints (20% body weight loss, Grade 3–4 neurologic symptoms, or predetermined time points)—mice are euthanized and brains are carefully excised. Intact brains are photographed, weighed, and processed for formalin-fixed paraffin-embedded (FFPE) sectioning. Coronal sections (10 µm) are stained with hematoxylin and eosin (H&E) for tumor morphology, and immunohistochemistry is performed for glial fibrillary acidic protein (GFAP), Ki-67, CD31, and cleaved caspase-3 to assess tumor burden, proliferation, vascularity, and apoptosis. Tumor volume is quantified by planimetry or digital pathology software.

Fig 2. CT-2A Orthotopic Mouse Model construction workflow.

Case Study-CT-2A Orthotopic Mouse Model Development

In a recent preclinical program, the CT-2A orthotopic model was employed to assess the intratumoral efficacy of a novel oncolytic virus engineered to selectively replicate within PTEN-deficient glioma cells while stimulating antitumor immunity. Following standardized stereotactic implantation, tumors were allowed to establish over a 10-day period, after which mice received either direct intratumoral injections of the investigational vector or a control buffer on Days 10, 13, and 16. Treated animals demonstrated a measurable delay in neurologic symptom progression and extended median survival compared to control cohorts, with postmortem histopathology revealing reduced tumor cross-sectional area, diminished Ki-67 staining, and increased CD8⁺ T-cell infiltration within the peritumoral region. These preclinical observations provided supportive efficacy and immunologic data to guide subsequent vector optimization and dosing regimen design for advanced in vivo pharmacology studies.

Why Choose Alfa Cytology?

Selecting Alfa Cytology as your preclinical partner for CT-2A orthotopic glioma studies means gaining access to a neuro-oncology-focused service platform that combines surgical precision, advanced imaging infrastructure, and rigorous quality assurance. Our core differentiators include:

• Proficiency in stereotactic neurosurgery for murine intracranial tumor models, with validated coordinates and injection parameters that ensure high engraftment rates and low perioperative mortality.
• Access to small-animal MRI and optional BLI capabilities for noninvasive, longitudinal assessment of tumor growth, edema, and treatment response without serial sacrifice.
• Capability to propagate both monolayer and neurosphere-derived CT-2A variants, enabling comparative studies of glioma stem cell biology and immunosuppressive microenvironment dynamics.
• Flexible study designs accommodating diverse therapeutic modalities—including small molecules, biologics, oncolytic viruses, cell therapies, and convection-enhanced delivery platforms—with customizable dosing schedules and combination arms.
• Comprehensive neuropathology suite featuring H&E, IHC, immunofluorescence, and digital image analysis for quantitative assessment of tumor burden, vascularity, proliferation, apoptosis, and immune cell infiltration.
• Dedicated scientific project management with transparent milestone reporting, real-time data sharing, and adaptive protocol amendments to align with evolving research priorities and publication timelines.

Contact Us

If your research program demands a translationally robust, immunocompetent glioma model to evaluate novel therapeutic strategies against high-grade brain tumors, Alfa Cytology is prepared to advance your preclinical objectives. Reach out to our scientific team to discuss your specific study design, review available model configurations—including monolayer and neurosphere-derived CT-2A variants—and receive a tailored proposal aligned with your timeline and budget. Contact us today to partner with a specialized CRO committed to accelerating your neuro-oncology discovery pipeline.

For research use only. Not intended for any clinical use.